Investing.com - Financial Markets Worldwide

Esperion Therapeutics Inc (ESPR)

NASDAQ
Currency in USD
1.370
-0.040(-2.84%)
Real-time Data·
ESPR Scorecard
Full Analysis
Operates with a significant debt burden
Earnings results expected in 5 days
Fair Value
Unlock Value
Day's Range
1.3601.410
52 wk Range
0.6933.940
Key Statistics
Edit
Prev. Close
1.41
Open
1.38
Day's Range
1.36-1.41
52 wk Range
0.693-3.94
Volume
1.21M
Average Volume (3m)
4.92M
1-Year Change
-39.22%
Book Value / Share
-2.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ESPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Buy
Price Target
5.786
Upside
+322.31%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 8
Quickly burning through cash
Unlock InvestingPro

Esperion Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Esperion Therapeutics Inc Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
304
Market
United States

Esperion Therapeutics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS missed at -$0.21 vs -$0.16 forecast; revenue beat at $65M, up 63% YoY
  • U.S. net product revenue rose 41% YoY; stock fell 0.95% premarket despite strong sales
  • Company targets triple combination product launch in 2027, expands international partnerships
  • 2025 operating expenses projected between $215M-$235M; cash position at $114.6M
  • CEO emphasizes commitment to cardiovascular risk reduction; CFO highlights strategic transition
Last Updated: 06/05/2025, 14:04
Read Full Transcript

Compare ESPR to Peers and Sector

Metrics to compare
ESPR
Peers
Sector
Relationship
P/E Ratio
−1.8x−0.1x−0.5x
PEG Ratio
0.100.020.00
Price/Book
−0.6x1.3x2.6x
Price / LTM Sales
1.0x1.6x3.3x
Upside (Analyst Target)
182.7%133.5%42.4%
Fair Value Upside
Unlock26.8%7.2%Unlock

Analyst Ratings

4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.786
(+322.31% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.21 / -0.16
Revenue / Forecast
64.99M / 50.64M
EPS Revisions
a
a
Unlock
Last 90 days

ESPR Income Statement

People Also Watch

Sarepta
16.90
SRPT
+0.90%
Altimmune
3.71
ALT
+1.51%
Ast Spacemobile
54.762
ASTS
+0.87%
Oklo Inc
79.02
OKLO
+4.48%
D Wave Quantum
18.160
QBTS
+6.45%

FAQ

What Stock Exchange Does Esperion Trade On?

Esperion is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Esperion?

The stock symbol for Esperion is "ESPR."

What Is the Esperion Market Cap?

As of today, Esperion market cap is 270.54M.

What Is Esperion's Earnings Per Share (TTM)?

The Esperion EPS (TTM) is -0.79.

When Is the Next Esperion Earnings Date?

Esperion will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is ESPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Esperion Stock Split?

Esperion has split 0 times.

How Many Employees Does Esperion Have?

Esperion has 304 employees.

What is the current trading status of Esperion (ESPR)?

As of 31 Jul 2025, Esperion (ESPR) is trading at a price of 1.37, with a previous close of 1.41. The stock has fluctuated within a day range of 1.36 to 1.41, while its 52-week range spans from 0.69 to 3.94.

What Is Esperion (ESPR) Price Target According to Analysts?

The average 12-month price target for Esperion is USD5.78571, with a high estimate of USD16 and a low estimate of USD1.5. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +322.31% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.